title: Intravenously injected insulin-like growth factor (IGF) I/IGF binding protein-3 complex exerts insulin-like effects in hypophysectomized, but not in normal rats.
abstract: Insulin-like growth factor (IGF) circulates in blood in two large molecular mass forms of 150 and 40 kD. Under normal conditions, most of the IGF is bound to the 150-kD complex by which it is retained in the circulation and therefore unable to exert acute insulin-like actions. The aim of this study was to answer the question whether or not IGF in the 40-kD complex is bioavailable to insulin target tissues and thus can cause acute insulin-like effects in vivo. Intravenously injected 1:1 molar recombinant human (rh) IGF I/rhIGF binding protein (BP)-3 complex lowered blood glucose and stimulated glycogen synthesis in diaphragm of hypophysectomized, but not of normal rats. The serum half-lives of the two components of the complex were similar to each other, but considerably shorter in hypox than in normal rats. On neutral gel filtration of serum both components of the injected complex appeared predominantly in the 150-kD region in normal rats. In hypox rats which lack the 150-kD complex they were found in the 40-kD region and disappeared rapidly from the circulation. We conclude that in the absence of the 150-kD complex, IGF associated with the 40-kD complex can rapidly leave the vascular compartment, reach insulin or type 1 IGF receptors and exert acute insulin-like effects.
authors.affiliation: Department of Medicine, University Hospital, Zürich, Switzerland.
authors.forename: J
authors.initials: J
authors.lastname: Zapf
authors.forename: C
authors.initials: C
authors.lastname: Hauri
authors.forename: E
authors.initials: E
authors.lastname: Futo
authors.forename: M
authors.initials: M
authors.lastname: Hussain
authors.forename: J
authors.initials: J
authors.lastname: Rutishauser
authors.forename: C A
authors.initials: CA
authors.lastname: Maack
authors.forename: E R
authors.initials: ER
authors.lastname: Froesch
mesh_terms: D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D002352:Carrier Proteins / Q000494:pharmacology*; D003964:Diaphragm / Q000378:metabolism; D004347:Drug Interactions; D006003:Glycogen / Q000378:metabolism; D006207:Half-Life; D007016:Hypophysectomy; D007275:Injections, Intravenous; D007328:Insulin / Q000494:pharmacology; D018969:Insulin-Like Growth Factor Binding Proteins; D007334:Insulin-Like Growth Factor I / Q000494:pharmacology*; D046911:Macromolecular Substances; D008297:Male; D011485:Protein Binding; D051381:Rats; D011994:Recombinant Proteins / Q000494:pharmacology
chemical_list: D001786:Blood Glucose; D002352:Carrier Proteins; D007328:Insulin; D018969:Insulin-Like Growth Factor Binding Proteins; D046911:Macromolecular Substances; D011994:Recombinant Proteins; D007334:Insulin-Like Growth Factor I; D006003:Glycogen